Argenx To Present At 40th Annual J.P. Morgan Healthcare Conference

January 3 , 202 2 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive…

January 3 , 202 2 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 7:30 a.m. ET.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only FDA approved neonatal Fc receptor blocker, VYVGART (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn,   Twitter, and Instagram.

For further information, please contact:

Media: Kelsey KirkKKirk@argenx.com

Joke Comijn (EU)jcomijn@argenx.com

Investors: Beth DelGiaccobdelgiacco@argenx.com

Michelle Greenblattmgreenblatt@argenx.com

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Debate presidencial: qué dijeron los candidatos en materia económica thumbnail

Debate presidencial: qué dijeron los candidatos en materia económica

Debate presidencial de EL TIEMPO Casa Editorial y Grupo Semana.EL TIEMPO POR: enero 25 de 2022 - 10:36 a. m. 2022-01-25 2022-01-25 Tras un debate álgido,  los precandidatos Sergio Fajardo, Camilo Romero, Alejandro Gaviria, Federico Gutiérrez, Juan Manuel Galán, Ingrid Betancourt, Francia Márquez, Gustavo Petro, Óscar Iván Zuluaga y Rodolfo Hernández dieron a conocer cuál sería…
Read More
Russia's invasion of Ukraine throws another wrench into supply chains thumbnail

Russia’s invasion of Ukraine throws another wrench into supply chains

Russia's invasion of Ukraine this week threatens to further upend international supply chains still reeling from the protracted COVID-19 pandemic and other disruptions, experts say. A growing list of companies are halting operations in the region in response to the escalating conflict. A.P. Moller-Maersk will refrain from calling any ports in Ukraine "until further notice,"…
Read More
XTRA: The Revolution Staking Platform thumbnail

XTRA: The Revolution Staking Platform

sponsored XTRA is a DeFI staking platform that offers over 14,7 to 45,2% APY. It is trustless, capital-backed, secure, powerful, extremely profitable, and easy to use. The best feature of XTRA is its decentralized GUARANTEE FUND that secures up to 90% of your token purchase price. The first listing of XTRA took place on the…
Read More
NZD/JPY Price Analysis: Cross extends gains to multi-year highs past 97.50 thumbnail

NZD/JPY Price Analysis: Cross extends gains to multi-year highs past 97.50

The cross continued its upward journey, reaching new cycle highs above 97.50, levels not seen since July 2007. The daily chart shows intense bullish sentiment, with the Yen weakening against its peers. Indicators are approaching overbought conditions which might limit the upside. On Friday, the NZD/JPY cross extended advances and established multi-year highs above  97.50.
Read More
Index Of News
Total
0
Share